141 related articles for article (PubMed ID: 38179743)
1. Metabolism-Related Prognostic Biomarkers, Purine Metabolism and Anti-Tumor Immunity in Colon Adenocarcinoma.
Liu H; Zhang Y; Zhang Q; Zhang T; Lu T
Front Biosci (Landmark Ed); 2023 Dec; 28(12):328. PubMed ID: 38179743
[TBL] [Abstract][Full Text] [Related]
2. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
3. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
[TBL] [Abstract][Full Text] [Related]
4. An integrated bioinformatic investigation of mitochondrial energy metabolism genes in colon adenocarcinoma followed by preliminary validation of CPT2 in tumor immune infiltration.
Cao Z; Lin J; Fu G; Niu L; Yang Z; Cai W
Front Immunol; 2022; 13():959967. PubMed ID: 36177002
[TBL] [Abstract][Full Text] [Related]
5. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
Gao H; Xing F
BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
[TBL] [Abstract][Full Text] [Related]
6. Investigating gene signatures associated with immunity in colon adenocarcinoma to predict the immunotherapy effectiveness using NFM and WGCNA algorithms.
Liang W; Yang X; Li X; Wang P; Zhu Z; Liu S; Xu D; Zhi X; Xue J
Aging (Albany NY); 2024 May; 16(9):7596-7621. PubMed ID: 38742936
[TBL] [Abstract][Full Text] [Related]
7. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
8. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
9. Identification of sixteen metabolic genes as potential biomarkers for colon adenocarcinoma.
Zhao F; Liu Y; Gu X; Zhang B; Song C; Cui B
J BUON; 2021; 26(4):1252-1259. PubMed ID: 34564978
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
11. Developing a prognosis and chemotherapy evaluating model for colon adenocarcinoma based on mitotic catastrophe-related genes.
Liu Y; Zhao Y; Zhang S; Rong S; He S; Hua L; Wang X; Chen H
Sci Rep; 2024 Jan; 14(1):1655. PubMed ID: 38238555
[TBL] [Abstract][Full Text] [Related]
12. Construction and validation of a prognostic model for colon adenocarcinoma based on bile acid metabolism-related genes.
Luo Q; Zhou P; Chang S; Huang Z; Zeng X
Sci Rep; 2023 Aug; 13(1):12728. PubMed ID: 37543674
[TBL] [Abstract][Full Text] [Related]
13. Construction of a prognostic model based on genes associated with mitochondrial energy metabolic pathway in colon adenocarcinoma and its clinical significance.
Zhang X; Liang C; Zhou B; Pang L
J Mol Recognit; 2023 Aug; 36(8):e3044. PubMed ID: 37322568
[TBL] [Abstract][Full Text] [Related]
14. In silico development and clinical validation of novel 8 gene signature based on lipid metabolism related genes in colon adenocarcinoma.
Jiang C; Liu Y; Wen S; Xu C; Gu L
Pharmacol Res; 2021 Jul; 169():105644. PubMed ID: 33940186
[TBL] [Abstract][Full Text] [Related]
15. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
Front Immunol; 2022; 13():881359. PubMed ID: 35911752
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
Wang H; Wang W; Wang Z; Li X
Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
[TBL] [Abstract][Full Text] [Related]
17. Construction of a novel cancer-associated fibroblast-related signature to predict clinical outcome and immune response in colon adenocarcinoma.
Zheng L; Zhang J; Ye Y; Shi Z; Huang Y; Zhang M; Gui Z; Li P; Qin H; Sun W; Zhang M
Aging (Albany NY); 2023 Sep; 15(18):9521-9543. PubMed ID: 37724904
[TBL] [Abstract][Full Text] [Related]
18. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
[No Abstract] [Full Text] [Related]
19. Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma.
Nan H; Guo P; Fan J; Zeng W; Hu C; Zheng C; Pan B; Cao Y; Ge Y; Xue X; Li W; Lin K
Front Immunol; 2023; 14():1093974. PubMed ID: 36949947
[TBL] [Abstract][Full Text] [Related]
20. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
Front Oncol; 2022; 12():876660. PubMed ID: 35747790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
